Last reviewed · How we verify
Autologous platelet rich plasma eye drops
Autologous platelet rich plasma eye drops, developed by Assiut University, are currently marketed but lack detailed revenue figures and primary indication data. The key strength lies in the unique autologous formulation, which may offer personalized treatment options. The primary risk is the key composition patent expiry in 2028, potentially leading to increased competition.
At a glance
| Generic name | Autologous platelet rich plasma eye drops |
|---|---|
| Also known as | PRP eye drops |
| Sponsor | Assiut University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Autologous Platelet-rich Plasma in the Treatment of Persistent Epithelial Defects (NA)
- Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy (NA)
- Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease (PHASE3)
- Platelet Rich Plasma in Corneal Surface Diseases (PHASE3)
- Platelet Rich Plasma as a Treatment For Resistant Corneal Ulcers (PHASE4)
- Platelet Rich Plasma Eye Drops for Treatment of Ocular Surface Disease (PHASE4)
- Management of Deep Retinal Capillary Ischemia by Electromagnetic Stimulation and Platelet- Rich Plasma (NA)
- Ocular Surface Syndrome Post-lasik, Outcomes of Treatment With Platelet Rich Plasma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: